Description
Rituximab humanised monoclonal antibody is a therapeutic reagent directed against the human CD20 cell surface antigen. Rituximab is a therapeutic reagent directed against the human CD20 cell surface antigen. This antibody has been used to detect Rituximab bound to the surface of the Raji B cell line, however detection of Rituximab bound 'in vivo' to B CLL cells has not been demonstrated. It is possible that complement deposition on Rituximab opsonised cells inhibits binding of the anti-Rituximab antibody to cell bound Rituximab.
Bioinformatics
| Alternate Names |
- B lymphocyte antigen CD20
- B lymphocyte surface antigen B1
- Bp35
- CD20
- LEU 16
- LEU16
- Membrane spanning 4 domains subfamily A member 1
- MS4A1
- Rituximab
|
